Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Español Near me My list Help
US Patient GuideUSA
Surprise me
Brand-name prescription medicine

Ogivri

Generic name: Trastuzumab

FDA application holder: Mylan GMBH

Strengths and generic versions Official label

Official data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the NDC Directory, Drugs@FDA, the official labels and recall reports; pharmacy costs come from the Centers for Medicare & Medicaid Services (CMS). Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or switch any medicine, including a switch between a brand and a generic.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

At a glance

2Strengths and forms
2Same medicine, other names
2017FDA approval
0Recalls (FDA reports)

Quick answers

What is Ogivri?
Ogivri is a brand name of Trastuzumab, a prescription medicine. The FDA NDC Directory lists 3 Ogivri products in 2 strengths and forms.
Who makes Ogivri?
Mylan GMBH holds the FDA application for Ogivri (BLA761074, approved December 1, 2017). 1 other company (repackagers or distributors) also list Ogivri products.
Is there a generic or store brand of Ogivri?
Yes. The FDA NDC Directory lists 2 other products with the same active ingredients, strength and form as a Ogivri product. Ask your pharmacist whether one is right for you.
Has Ogivri been recalled?
No recall linked to Ogivri products (by their NDC code or label) appears in the FDA enforcement reports we use.

What Ogivri is

Each Ogivri product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.

Trastuzumab · prescription medicine

Strength and formProduct namesSame medicine, other namesLabel
trastuzumab 150 mg/7.4 mL
injection, powder, lyophilized, for solution (intravenous)		 Ogivri 1 product, 1 company DailyMed
trastuzumab 420 mg/20 mL
injection, powder, lyophilized, for solution (intravenous)		 Ogivri 1 product, 1 company DailyMed

Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Trastuzumab →

FDA approval

  • BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
FDA applications of Ogivri products (Drugs@FDA)
ApplicationHolderFirst approvedProducts
BLA761074Mylan GMBHDecember 1, 20173

Companies that list Ogivri

The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Ogivri products.

Recalls

No recall linked to Ogivri products (by their NDC code or label) appears in the FDA enforcement reports.

Sources

  1. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  2. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026

Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.

Report an error → · Information for medicine makers